Web-survey for atopic dermatitis control in Japan

Web-survey for Atopic Dermatitis Control Tool (ADCT) and Other AD Assessment Tools in Japan - Web-survey for ADCT in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045563

Enrollment

6200

Registered

2021-09-24

Start date

2021-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Submitted their informed consent and agreed to participate in the survey. -Responded that they have been diagnosed with atopic dermatitis by a doctor in the past. -Have visited a medical institution in Japan for atopic dermatitis in the past six months. -Males and females 20 years old or older who live in Japan and understand and can respond to the questionnaire in Japanese

Exclusion criteria

Exclusion criteria: -Applicable to inappropriate responses

Design outcomes

Primary

Measure	Time frame
Correlation coefficient between the ADCT score and each of the four following scores (DLQI/POEM/Worst Itch-NRS (WI-NRS)/GQ)	—

Secondary

Measure	Time frame
-ADCT scores overall and by demographic characteristics (demographic characteristics: Age, gender, occupation, annual income, household composition, area of residence, and lifestyle) -Demographic characteristics by dupilumab users and non-users -Dosing patterns of dupilumab users (how long administered, whether or not they have ever discontinued it, length of temporary discontinuations) -ADCT and four (DLQI/POEM/WI-NRS/GQ) scores among dupilumab users and non-users	—

Measure

Time frame

-ADCT scores overall and by demographic characteristics (demographic characteristics: Age, gender, occupation, annual income, household composition, area of residence, and lifestyle) -Demographic characteristics by dupilumab users and non-users -Dosing patterns of dupilumab users (how long administered, whether or not they have ever discontinued it, length of temporary discontinuations) -ADCT and four (DLQI/POEM/WI-NRS/GQ) scores among dupilumab users and non-users

—

Countries

Japan

Contacts

Public ContactTomoyuki Kusaka

Social Survey Research Information Co., Ltd. Healthcare BI & MA Service Division Health Outcomes Research

HOR@ssri.com03-6709-9710

Outcome results